Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

被引：0
|
作者：
Dominic Pilon
Erik Muser
Patrick Lefebvre
Rhiannon Kamstra
Bruno Emond
Kruti Joshi
机构：
[1] Groupe d’analyse,
[2] Ltée,undefined
[3] Janssen Scientific Affairs,undefined
[4] LLC,undefined
来源：
BMC Psychiatry | / 17卷
关键词：
Oral Atypical Antipsychotics (OAA); Healthcare Resource Utilization; Mean Monthly Cost; Medical Cost Savings; Higher Pharmacy Costs;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] A PRAGMATIC ANALYSIS COMPARING ONCE-MONTHLY PALIPERIDONE PALMITATE VERSUS DAILY ORAL ANTIPSYCHOTIC TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
    Starr, H. L.
    Bossie, C.
    Benson, C.
    Mao, Lian
    Alphs, L.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S334 - S334
  • [12] A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia
    Alphs, Larry
    Mao, Lian
    Starr, H. Lynn
    Benson, Carmela
    SCHIZOPHRENIA RESEARCH, 2016, 170 (2-3) : 259 - 264
  • [13] A Pragmatic Analysis Comparing Once-monthly Paliperidone Palmitate Versus Daily Oral Antipsychotic Treatment in Patients with Schizophrenia
    Alphs, Larry
    Benson, Carmela
    Bossie, Cynthia
    Mao, Lian
    Starr, H. Lynn
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S364 - S365
  • [14] Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse
    Zhdanava, Maryia
    Lin, Dee
    Lafeuille, Marie-Helene
    Ghelerter, Isabelle
    Morrison, Laura
    Lefebvre, Patrick
    Joshi, Kruti
    CLINICAL THERAPEUTICS, 2021, 43 (03) : 535 - 548
  • [15] Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
    Hargarter, L.
    Bergmans, P.
    Cherubin, P.
    Keim, S.
    Conca, A.
    Serrano-Blanco, A.
    Bitter, I.
    Bilanakis, N.
    Schreiner, A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (08) : 1043 - 1053
  • [16] Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
    El Khoury, Antoine C.
    Pilon, Dominic
    Morrison, Laura
    Shak, Nina
    Llaneza, Amanda
    Kim, Edward
    Lefebvre, Patrick
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 176 - 185
  • [17] Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Sliwa, Jennifer Kern
    Ma, Yi-Wen
    Alphs, Larry
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2011, 1 (04) : 111 - 124
  • [18] Persistence With and Adherence to Paliperidone Palmitate Once-Monthly Injection for Schizophrenia Treatment in China and Japan
    Wang, Huaning
    Zhang, Yongjing
    Liu, Jin
    Chi, Rui
    Wu, Tao
    Zhang, Ting
    Zhang, Lili
    Jiang, Kun
    Qiu, Hong
    Dong, Wentian
    Si, Tianmei
    JOURNAL OF CLINICAL PSYCHIATRY, 2022, 83 (01)
  • [19] Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
    Patel, Charmi
    Khoury, Antoine El
    Huang, Ahong
    Wang, Li
    Bashyal, Richa
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2020, 92
  • [20] TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION AMONG YOUNG ADULTS WITH SCHIZOPHRENIA TREATED WITH PALIPERIDONE PALMITATE OR ORAL ATYPICAL ANTIPSYCHOTICS
    Amos, T.
    El Khoury, A.
    Vlahiotis, A.
    Manjelievskaia, J.
    Cole, A.
    Juneau, P.
    VALUE IN HEALTH, 2018, 21 : S190 - S190
12345